Helix BioPharma Corp. Initiate Enrollment For Thirteen Cohort on Polish I/II Clinical Study of Its Lung Cancer Drug L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the thirteenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002”).

Helix BioPharma Corp. Announces Q3 Fiscal 2015 Results

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the third quarter of fiscal 2015, ended April 30, 2015.

HELIX BIOPHARMA CORP. Announces a Presentation at the Joint Conference of The Canadian Society For Pharmaceutical Science and The Canadian Chapter of the Controlled Release Society

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its Chief Scientific Officer, Dr. Heman Chao, has been invited to give an oral presentation at the 2015 Joint Conference of the Canadian Society For Pharmaceutical Science and the Canadian Chapter of the Controlled …